Weekly Investment Analysts’ Ratings Changes for AbbVie (ABBV)

AbbVie (NYSE: ABBV) has recently received a number of price target changes and ratings updates:

• 2/28/2026 – AbbVie was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 2/24/2026 – AbbVie is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $260.00 price target on the stock.
• 2/19/2026 – AbbVie is now covered by Barclays PLC. They set an “overweight” rating and a $275.00 price target on the stock.
• 2/19/2026 – AbbVie is now covered by Barclays PLC. They set an “overweight” rating and a $275.00 price target on the stock.
• 2/18/2026 – AbbVie had its price target raised by Piper Sandler from $289.00 to $299.00. They now have an “overweight” rating on the stock.
• 2/5/2026 – AbbVie had its “market perform” rating reaffirmed by Sanford C. Bernstein.
• 2/5/2026 – AbbVie had its price target lowered by UBS Group AG from $240.00 to $230.00. They now have a “neutral” rating on the stock.
• 2/5/2026 – AbbVie was upgraded by UBS Group AG to “hold”.
• 2/5/2026 – AbbVie had its price target raised by Morgan Stanley from $269.00 to $270.00. They now have an “overweight” rating on the stock.
• 2/4/2026 – AbbVie had its price target lowered by Evercore Inc from $232.00 to $228.00. They now have an “outperform” rating on the stock.
• 1/28/2026 – AbbVie had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $223.00 price target on the stock.
• 1/27/2026 – AbbVie had its price target lowered by Citigroup Inc. from $235.00 to $230.00. They now have a “neutral” rating on the stock.
• 1/21/2026 – AbbVie had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 1/20/2026 – AbbVie was given a new $275.00 price target by Berenberg Bank.
• 1/15/2026 – AbbVie had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $258.00 price target on the stock.
• 1/13/2026 – AbbVie had its “neutral” rating reaffirmed by UBS Group AG.
• 1/7/2026 – AbbVie is now covered by UBS Group AG. They set a “neutral” rating and a $240.00 price target on the stock.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s payout ratio is currently 293.22%.

Insider Activity

In other news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.25% of the stock is currently owned by insiders.

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.